西奥罗尼

Chiauranib

未知生产厂商

Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

生成 AI 研报

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

适应症

用于治疗经过2线系统化疗方案后疾病进展或复发的小细胞肺癌（SCLC）。

技术标识符

化学式: C₂₇H₂₁N₃O₃
CAS 编号: 1256349-48-0
UNII ID: F40IRN5981

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

USE OF CHIAURANIB IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN ANTITUMOR THERAPY
US 2023321074 A1申请人: SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD优先权: 2020
CN
EP
US
WO
5 件公开
PHARMACEUTICAL COMPOSITION COMPRISING PROTEIN KINASE INHIBITOR AND CHEMOTHERAPEUTIC DRUG AND USE THEREOF
US 2023117545 A1申请人: SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD优先权: 2020
EP
US
WO
4 件公开
PHARMACEUTICAL COMPOSITION COMPRISING ANTI-CTLA4-ANTI-PD-1 BISPECIFIC ANTIBODY AND CHIAURANIB
EP 4483877 A4申请人: AKESO PHARMACEUTICALS INC优先权: 2022
EP
US
WO
3 件公开
西奥罗尼在制备治疗急性髓系白血病药物的新用途
CN 109908143 B申请人: 厦门大学附属第一医院优先权: 2018
CN
西奥罗尼用于小细胞肺癌的治疗
CN 111728974 B申请人: 深圳微芯生物科技股份有限公司优先权: 2019
CN
Application of KDM5A gene and ATRX gene
CN 111733235 A申请人: SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD优先权: 2019
CN
一种抗双重打击淋巴瘤的联合用药物组合物及其应用
CN 111214475 B申请人: 厦门大学附属第一医院优先权: 2020
CN
Application of Chiauranib and drug combination thereof in treatment of non-hodgkin lymphoma
CN 113908159 A申请人: SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD优先权: 2020
CN
Application of RBM10 gene
CN 114058700 A申请人: SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD优先权: 2020
CN

药物